News & Events Press Releases Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction Sep 29, 2022 Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer May 25, 2022 Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases Mar 8, 2022 Upcoming Events Tuesday, June 21, 2022 11:00 A.M. EDT Baird Webcast: Baird's Biotech Discovery Series Past Events January 10, 2022 at 7:00 am EDT H.C. Wainwright 24th Annual Global Investment Virtual Conference
Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction Sep 29, 2022
Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer May 25, 2022
Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases Mar 8, 2022
